U.S. pharma giant copyright scrapped two experimental weight loss drugs very last year—a after-day-to-day pill, lotiglipron, on account of elevated liver enzymes plus a twice-each day capsule, danuglipron, as a consequence of sturdy side effects—but CEO Albert Bourla has said the company is decided to “Engage in and gain” from the obesity A